No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ — Inhibrx Biosciences, Inc….
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
